Company Profile

Scholar Rock Stock Price, News & Catalysts

Ticker:
SRRK
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

50.37 USD (+4.94%)

Close

Last updated: November 19, 2026

5.35B USD

Market cap

Why the stock is moving

As of Nov 19, 2026, SRRK closed up 4.94% at $50.37. No new same-company headline was identified in the current news window.

Company overview

Myostatin Biology

Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways.

Apitegromab

Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal muscular atrophy. It is designed as an add-on to therapies that address the underlying genetic cause.

Additional Pipeline

Scholar Rock is applying its platform to additional neuromuscular and metabolic indications where modulation of muscle biology may provide clinical benefit.

Commercial and Pipeline Expansion

Following the U.S. approval of ISEMBYLD in spinal muscular atrophy, Scholar Rock is pursuing European review, younger-patient development, and expansion of apitegromab into facioscapulohumeral muscular dystrophy.

Future catalysts

  • Topline data from the Phase 2 FORGE study of apitegromab in facioscapulohumeral muscular dystrophy by year-end 2026, with data sharing planned for early 2027.
  • CHMP opinion on the apitegromab MAA for spinal muscular atrophy in the first half of 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Scholar Rock (SRRK)?

Scholar Rock (SRRK) most recently closed at 50.37 USD, a +4.94% move versus the previous session.

What is the market cap of Scholar Rock (SRRK)?

Scholar Rock currently has a market capitalization of 5.35B USD on BioPharmSignal.

What does Scholar Rock do?

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal muscular atrophy....

On which exchange is SRRK stock listed?

Scholar Rock (SRRK) is associated with NASDAQ, United States, Biopharma.

What is apitegromab?

Topline data from the Phase 2 FORGE study of apitegromab in facioscapulohumeral muscular dystrophy by year-end 2026, with data sharing planned for early 2027.

Which conditions is Scholar Rock targeting with apitegromab?

Scholar Rock is associated with metabolic disease, genetic disease based on its company overview and current catalyst commentary.

How does Scholar Rock describe recent progress with apitegromab?

Topline data from the Phase 2 FORGE study of apitegromab in facioscapulohumeral muscular dystrophy by year-end 2026, with data sharing planned for early 2027.

What is Myostatin?

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms.